Conexeu Sciences (NASDAQ:CNXU) Shares Down 5.2% - Here's What Happened

Key Points

• Conexeu Sciences shares fell 5.2% to $5.27 in midday trading, reaching as low as $5.20, while trading volume rose 15% above its average.
• Analyst sentiment is mixed, with one Buy, one Hold, and one Sell rating; the consensus rating is Hold with a $20.00 price target.
• The early-stage medical device company reported a quarterly loss of $0.11 per share, while director Lynn Sebastian Purcell purchased 202,500 shares at $0.80 each, increasing their position by 8%.

Conexeu Sciences Inc. (NASDAQ:CNXU - Get Free Report)'s stock price dropped 5.2% during mid-day trading on Thursday . The stock traded as low as $5.20 and last traded at $5.27. Approximately 304,950 shares changed hands during trading, an increase of 15% from the average daily volume of 264,938 shares. The stock had previously closed at $5.56.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on CNXU shares. HC Wainwright began coverage on Conexeu Sciences in a research report on Monday, June 22nd. They set a "buy" rating and a $20.00 price objective on the stock. Weiss Ratings began coverage on Conexeu Sciences in a report on Monday, August 17th. They set a "sell (e-)" rating on the stock. Zacks Research upgraded shares of Conexeu Sciences to a "hold" rating in a report on Monday, June 29th. Finally, Wall Street Zen raised shares of Conexeu Sciences to a "hold" rating in a report on Saturday, May 30th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Conexeu Sciences presently has an average rating of "Hold" and a consensus price target of $20.00.

Conexeu Sciences Stock Performance

The stock has a market cap of $141.03 million and a PE ratio of -47.91. The firm has a 50-day moving average of $8.82.

Conexeu Sciences (NASDAQ:CNXU - Get Free Report) last announced its quarterly earnings data on Monday, June 15th. The company reported ($0.11) earnings per share (EPS) for the quarter. Research analysts forecast that Conexeu Sciences Inc. will post -0.4 EPS for the current year.

Insider Transactions at Conexeu Sciences

In related news, Director Lynn Sebastian Purcell purchased 202,500 shares of Conexeu Sciences stock in a transaction on Thursday, June 18th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $162,000.00. Following the completion of the acquisition, the director owned 2,734,240 shares of the company's stock, valued at $2,187,392. This trade represents a 8.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source